02

Jan 2018

Aurobindo receives FDA approval for Fondaparinux Sodium Injection!

On December 27, 2017 Aurobindo received FDA approval for Fondaparinux Sodium Injection which is used to prevent deep vein thrombosis (DVT). This approved product has an estimated market size of  $73 million for the twelve months ending October 2017 according to IMS. PR USFDA FA – Fondaparinux Sodium Injection

[...] Read more
18

Dec 2017

Making our way into the Oncology space

AuroMedics has big plans in the coming years. Breaking into the oncology space is one piece of that puzzle. Follow the link below for additional information Aurobindo aims at cancer as it climbs the value chain

[...] Read more
12

Dec 2017

AuroMedics makes a statement at ASHP Mid-Year 2017

December 03 through 06 of 2017 marked the 75th year of the annual ASHP Midyear Clinical Meeting. With attendance rising to 25,000, this is the largest gathering of pharmacy professionals in the world. AuroMedics was proud to have our largest presence with a custom 20×30 foot booth, which helped showcase some of our most in demand products

[...] Read more